PlainPharmaWatch

CMS Open Payments · Program Year 2024

Alcresta Therapeutics, Inc.

Alcresta Therapeutics, Inc. reported $170,171.73 in payments to 869 physicians and teaching hospitals across 869 transactions.

See the rankings → How this is sourced
$170.2K
Total payments
869
Transactions
869
Recipients
−$116.0K
General Payments vs PY2023

Alcresta Therapeutics, Inc. reported $170,171.73 in payments to 869 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #1048 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $195.82 per recipient across 3 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Alcresta Therapeutics, Inc. pairs below-median payment volume with a broadly spread payment pattern across many recipients.

#1048
of 1,925 companies
0.0%
of all US industry payments
0.2%
paid to its single top recipient
3
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Alcresta Therapeutics, Inc.'s CMS-reported General Payments decreased by $116.0K (−40.5%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: ALCRESTA THERAPEUTICS, INC.PY2023: ALCRESTA THERAPEUTICS, INC.PY2024: Alcresta Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$286.2KPY2024$170.2K
PY2023
$286,203.06
PY2024
$170,171.73

How Alcresta Therapeutics, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Alcresta Therapeutics, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$170,172 46th percentile higher than 46% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). This entry sits in this band. $242,294–$752,621: 270 reporting companies (14%). Above this entry. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Alcresta Therapeutics, Inc.

Averaging $195.82 per transaction and $195.82 per recipient, Alcresta Therapeutics, Inc.'s Program Year 2024 total comes to $170,171.73 across 869 transactions and 869 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1048 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 3 general-payment categories charted below, "Honoraria" is the largest at $126.2K across 50 transactions, 74.2% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Honoraria" leads Alcresta Therapeutics, Inc.'s 3-category general-payment breakdown at $126.2K, 74.2% of the reported total.

How Alcresta Therapeutics, Inc. divides its payments

Ranked by total dollars reported per category

1. Honoraria$126.2K2. Food and Beverage$33.9K3. Travel and Lodging$10.1K
Payment Type Amount Transactions
Honoraria $126.2K 50
Food and Beverage $33.9K 766
Travel and Lodging $10.1K 53

Recipient Concentration in General Payments

The five largest recipient relationships account for $113,352.07 (66.6%) of $170,171.73 in this company's General Payments records across 556 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Alcresta Therapeutics, Inc.

The five named recipients with the highest reported General Payments from this company

Valeria Cohran$41.7KCandi Jump$23.9KStephanie Abrams$23.2KAkash Pandey$15.0KMary Garcia$9.5K
  1. 1

    Valeria Cohran

    $41,743.08 across 48 reported transactions

  2. 2

    Candi Jump

    $23,944.58 across 25 reported transactions

  3. 3

    Stephanie Abrams

    $23,158.38 across 20 reported transactions

  4. 4

    Akash Pandey

    $15,034.27 across 13 reported transactions

  5. 5

    Mary Garcia

    $9,471.76 across 8 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $195.82. Average per recipient: $195.82.

Total Amount

$170,171.73

Avg per Transaction

$195.82

Avg per Recipient

$195.82

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Alcresta Therapeutics, Inc. Share

0.0%

#1048 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Alcresta Therapeutics, Inc.

Clozex Medical Inc

$170.2K 6 recipients

Draeger Medical Systems, Inc

$169.2K 95 recipients

Quanta Dialysis Technologies Inc

$169.2K 2 recipients

Hexal AG

$168.9K 19 recipients

Carl Zeiss Meditec Digital Innovations LLC

$167.7K 34 recipients

Bioprotect Medical, Inc.

$165.6K 954 recipients

Frequently Asked Questions

How much did Alcresta Therapeutics, Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $170,171.73 from Alcresta Therapeutics, Inc. to physicians and hospitals across 869 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Alcresta Therapeutics, Inc.? ▾
Averaging $195.82 per recipient, Alcresta Therapeutics, Inc.'s 2024 payments reached 869 physicians and teaching hospitals.
What types of payments did Alcresta Therapeutics, Inc. make? ▾
Alcresta Therapeutics, Inc. made 3 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Honoraria" at $126.2K, representing 74.2% of the company's reported total.
How does Alcresta Therapeutics, Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Alcresta Therapeutics, Inc. ranks #1048 by total payment amount.
What is the average payment size from Alcresta Therapeutics, Inc.? ▾
Alcresta Therapeutics, Inc.'s 869 transactions to 869 recipients in 2024 averaged $195.82 per transaction.
Where does the payment data for Alcresta Therapeutics, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Alcresta Therapeutics, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.